Lapatinib: An Oral Dual Tyrosine Kinase Inhibitor for HER-2-Positive Breast Cancer | Zendy

Sagar Sardesai | Zendy; Anna Maria Storniolo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lapatinib: An Oral Dual Tyrosine Kinase Inhibitor for HER-2-Positive Breast Cancer

Author(s) -

Sagar Sardesai,

Anna Maria Storniolo

Publication year - 2015

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/whe.15.9

Subject(s) - lapatinib , medicine , trastuzumab , capecitabine , breast cancer , tyrosine kinase inhibitor , oncology , letrozole , cancer , metastatic breast cancer , pertuzumab , tamoxifen , colorectal cancer

Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA. A quarter of all newly diagnosed cases are characterized by overexpression of HER-2 which is associated with poor prognosis. In March 2007, lapatinib, an oral dual-tyrosine kinase inhibitor was approved in combination with capecitabine for metastatic HER-2-positive breast cancer that has progressed on prior trastuzumab therapy, and in combination with letrozole for postmenopausal women with HER-2 and hormone receptor-positive advanced breast cancer. In the future, lapatinib may play an important role in dual HER-2 blockade with trastuzumab and other targeted agents for women with HER-2-overexpressing breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research